Literature DB >> 27097810

The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review.

Caro E Sluijter1,2, Luc R C W van Lonkhuijzen3, Henk-Jan van Slooten4,5, Iris D Nagtegaal6,4, Lucy I H Overbeek4.   

Abstract

Pathology reporting is evolving from a traditional narrative report to a more structured synoptic report. Narrative reporting can cause misinterpretation due to lack of information and structure. In this systematic review, we evaluate the impact of synoptic reporting on completeness of pathology reports and quality of pathology evaluation for solid tumours. Pubmed, Embase and Cochrane databases were systematically searched to identify studies describing the effect of synoptic reporting implementation on completeness of reporting and quality of pathology evaluation of solid malignant tumours. Thirty-three studies met the inclusion criteria. All studies, except one, reported an increased overall completeness of pathology reports after introduction of synoptic reporting (SR). Most frequently studied cancers were breast (n = 9) and colorectal cancer (n = 16). For breast cancer, narrative reports adequately described 'tumour type' and 'nodal status'. Synoptic reporting resulted in improved description of 'resection margins', 'DCIS size', 'location' and 'presence of calcifications'. For colorectal cancer, narrative reports adequately reported 'tumour type', 'invasion depth', 'lymph node counts' and 'nodal status'. Synoptic reporting resulted in increased reporting of 'circumferential margin', 'resection margin', 'perineural invasion' and 'lymphovascular invasion'. In addition, increased numbers of reported lymph nodes were found in synoptic reports. Narrative reports of other cancer types described the traditional parameters adequately, whereas for 'resection margins' and '(lympho)vascular/perineural invasion', implementation of synoptic reporting was necessary. Synoptic reporting results in improved reporting of clinical relevant data. Demonstration of clinical impact of this improved method of pathology reporting is required for successful introduction and implementation in daily pathology practice.

Entities:  

Keywords:  Breast cancer; Checklist; Colorectal carcinoma; Completeness; Guideline; Narrative reporting; Pathology; Proforma; Quality; Synoptic reporting; Template

Mesh:

Year:  2016        PMID: 27097810      PMCID: PMC4887530          DOI: 10.1007/s00428-016-1935-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


Introduction

The ever increasing complexity of cancer treatment requires a high-quality diagnostic process, in which anatomic pathology plays a central role. A complete and clear anatomic pathology report forms the basis for optimal treatment decisions [1]. Depending on cancer type, an increasing number of parameters need to be reported by pathologists [2-5]. The way anatomic pathology reports are constructed needs to adapt to the continuous increase in complexity of reported diagnostic data [6]. There is a spectrum in the way pathology results are reported. This spectrum is divided into six levels by Srigley et al. [6]. Traditionally, a report consists of the following three paragraphs: macroscopy, microscopy and conclusion all completed with free text and without any further guidelines. These traditional narrative pathology reports (NRs) are considered level 1 reporting. NRs are still the standard in most jurisdictions, even though they are prone to misinterpretation [7] and do not always contain all mandatory information [8-16]. Level three consists of a synoptic-like structured format. With this method, the pathologist follows a checklist per cancer type to ensure that all mandatory parameters are reported. The layout of this type of reporting can still be narrative. More recently, synoptic reporting (SR) has been introduced in pathology. With SR, an electronic reporting module is used with standardised reporting language, multiple-choice answering of mandatory pathology parameters and automated generation of the conclusion (such as TNM stage). Generating a diagnostic report using such a system is much more comparable to filling out a form in an internet browser than it is to narrative reporting using speech recognition software. The result is a well-structured overview of the mandatory parameters for the pathology report (level 6). All levels are described in detail by Srigley et al. [6]. SR has been implemented in several settings all over the world [17]. However, an overview of the effect of SR on the completeness of pathology reports and quality of pathology evaluation in cancer diagnosis is lacking. In the current review, we evaluated the impact of the introduction of SR. We hypothesised that the implementation of SR improved both the completeness of anatomic pathology reports (per parameter and overall) as well as the inherent quality of anatomic pathologic evaluation of cancer specimens.

Materials and methods

To identify studies that described the effect of SR on completeness of reporting and quality of pathology evaluation of solid malignant tumours, a systematic literature search was performed.

Literature search

A combination of search terms in Pubmed, Embase and Cochrane was used to perform the literature search. For the search, we included variations of the following terms: ‘synoptic’, ‘checklist’, ‘template’, ‘pathologic’, ‘histopathology’ and ‘report’. In addition, reference lists of selected papers were manually searched (Online resource 1 describes the search terms in detail). The literature search was performed on September 30, 2015. Studies were included if studies investigated human subjects, pathology, solid tumours, SR and histology. Selection was first based on title and subsequently on abstract. Only original studies evaluating the effect of SR versus NR of solid malignant tumours were selected. (Conference) abstracts, case reports, editorials, letters and studies for which the full text was not available were excluded. Only studies describing quantitative outcomes of the comparison of SR with NR were included. Therefore, we excluded studies that only described a format of pathology reporting before implementation of SR that described the development of a SR module or the implementation strategy for SR. Two independent investigators (CS and LvL) reviewed each full text report for eligibility. From each included article, data was extracted on country of study, year and period of study, study design, cancer type, level of reporting before and after the implementation of SR [6], origin of guideline on which the synoptic data parameters are based, outcome measures, results and authors’ conclusion. The format or level of SR as described by Srigley et al. [6] was determined to categorise the studies.

Outcome measures

The outcome measures evaluated in this systematic review were completeness of the pathology reports and the quality of pathology evaluation. We used two definitions for completeness of pathology reports: (1) overall completeness, the proportion of pathology reports containing all mandatory pathology parameters in a given time frame, and (2) parameter-specific completeness, the proportion of pathology reports in which an individual parameter was present in a given time frame. Both definitions were applied to the selected studies. Quality of pathology evaluation was defined as the proportion of pathology reports in which the informational content corresponds to established quality indicators, such as lymph node numbers, presence of extramural vascular invasion and resection margins.

Data evaluation

The studies were categorised based on cancer type and the implemented level of SR (level 3 versus ≥level 4). To compare completeness, absolute numerical data in studies were converted into percentages. We included parameters that were reported in at least two independent studies. For readability, in the tables, we included only parameters that were reported in at least three independent studies. There is no established definition for sufficient reporting of a parameter. We considered a parameter sufficiently reported if the proportion of pathology reports containing the parameter was greater than 90 % in all the studies that studied the parameter, per cancer type. This percentage was based on definitions used in a number of other studies [18-22].

Results

A total of 3252 potentially relevant studies were retrieved by the database search. After removing duplicates, 2338 studies remained (Fig. 1). We excluded 2156 studies based on title, another 111 studies based on abstract or full text and 38 studies because the full-text article was not available. The remaining 33 studies were included for this review [6, 18–21, 23–52].
Fig. 1

Flowchart of search strategy

Flowchart of search strategy

Characteristics of studies

Table 1 summarises the characteristics of the 33 included studies. Twenty-three studies had a cross-sectional design and ten a case-control design. The studies originated from the following countries: the UK (n = 7), Australia (n = 6), Canada (n = 5), the USA (n = 4), Norway (n = 4), Germany (n = 2), the Czech Republic, Ireland, Italy, Sri Lanka and Sweden (all n = 1). Ten different types of cancer were covered in the studies. Most covered cancer types were colorectal (n = 16), breast (n = 9) and prostate cancers (n = 6). Twenty-three out of the 33 studies implemented a checklist format (level 3); the other ten studies implemented a higher SR level (≥level 4). Some studies described a two-step process of implementing SR level 4 or higher [6, 18, 23–25, 31, 35, 42, 47]. The SR modules were based on different guidelines, the College of American Pathologists (CAP; n = 12), the Royal College of Pathologists (RCP; n = 9) and other guidelines (n = 5). Some SR modules were based on expert opinion of a pathologist (n = 7).
Table 1

Characteristic of included studies

ArticleCountryCancer typeNumber of subjects (n)Study design (CC or CS)Level synoptic reportingOrigin guidelines
BeforeStep 1Step 2
Appleton [23]UKBreast40CS123NHSBSP
Aumann [24]GermanyProstate1049CS135CAP
Aumann [25]GermanyLung878CS135CAP
Austin [19]AustraliaBreast402CS13ACN
Beattie [26]IrelandColorectal171CC13RCP
Branston [28]UKBreast and colorectal2042CC14RCP
Buchwald [29]SwedenColon302CC13Own
Casati [30]NorwayColorectal1221CC11 and 5RCP
Chan [18]CanadaColorectal407CS134CAP
Cross [31]UKColorectal272CS123RCP
Gill [20]AustraliaPancreatic177CC13CAP
Hammond [32]USABreast796CS13Own
Hassel [33]USABreast, prostate and melanoma368CC14CAP
Haugland [34]NorwayColorectal650CS15RCP
Haydu [35]AustraliaMelanoma3784CS131 and 32008 Melanoma Guidelines
Idowu [36]USABreast, colorectal and prostate2125CS13CAP
Ihnat [37]Czech RepublicColorectal177CC13CAP
Kahn [38]AustraliaThyroid448CS13RCPA
Karim [39]AustraliaMelanoma1692CC13Own
Mathers [40]UKBreast100CC13RCP
McEvoy [41]AustraliaBreast1649CS?3NHMRC
Messenger [42]CanadaRectal498CS136CAP
Porter, 2013 [43]CanadaRectal197CS13Own
Reid, 2000 [44]UKUterine and cervix349CS13Own
Renshaw, 2014 [45]USAAll synoptic pathology reports6193CS123CAP
Rigby, 2000 [46]UKColorectal98CS13RCP
Siriwardana [21]Sri LankaColorectal168CS13RCP
Srigley [47]CanadaBreast, lung, endometrium, colorectal, and prostate7594CS136CAP
Srigley [6]CanadaColorectal and prostateAll reportsCS136CAP
Ventura [48]ItalyProstate70CC13CAP
Westgaard [49]NorwayPancreatic506CS13Own
Westgaard [50]NorwayPancreatic218CS13Own
Woods [51]UKColorectal953CS13RCP

UK United Kingdom, USA United States of America, CC case-control, CS cross sectoral, NHSBSP National Health Service Breast Screening Programme, CAP College of American Pathologists, ACN Australian Cancer Network, RCP Royal College of Pathologists, RCPA Royal College of Pathologists Australasia, NHMRC National Health and Medical Research Council

Characteristic of included studies UK United Kingdom, USA United States of America, CC case-control, CS cross sectoral, NHSBSP National Health Service Breast Screening Programme, CAP College of American Pathologists, ACN Australian Cancer Network, RCP Royal College of Pathologists, RCPA Royal College of Pathologists Australasia, NHMRC National Health and Medical Research Council

Completeness of pathology reports

Overall completeness

Out of the 14 studies [21, 23–25, 28, 30, 32, 33, 36, 38, 40, 45–47] that reported the effect of SR on the overall completeness of a pathology report, 13 showed an increased overall completeness, for several cancer types and SR levels (Fig. 2). SR was associated with an increased probability of providing information on the mandatory parameters [23-25] and a decrease in the number of missing parameters in a pathology report [36, 48]. The study that failed to show improved completeness [33] commented on the restricted list of parameters in the SR as defined by CAP. For example, in the guidelines as defined by CAP, SR description of specimen type lacked specific histological codes, whereas in NR, these histological codes could be included.
Fig. 2

Impact of synoptic reporting on overall completeness of a pathology report. Fourteen studies [21, 23–25, 28, 30, 32, 33, 36, 38, 40, 45–47] reported the effect of synoptic reporting on the overall completeness of a Pathology report (definition 1). Thirteen studies showed an increased overall completeness, independent of cancer type or synoptic reporting level of the module. In contrast, only one article [33] described that the SR was less complete than the NR

Impact of synoptic reporting on overall completeness of a pathology report. Fourteen studies [21, 23–25, 28, 30, 32, 33, 36, 38, 40, 45–47] reported the effect of synoptic reporting on the overall completeness of a Pathology report (definition 1). Thirteen studies showed an increased overall completeness, independent of cancer type or synoptic reporting level of the module. In contrast, only one article [33] described that the SR was less complete than the NR

Parameter-specific completeness

Five studies described the impact of SR on parameter-specific completeness in breast cancer. Four studies described the implementation of SR level 3 (Table 2). The results of the fifth article of Branston et al. [28], which implemented SR level 4, were calculated as the percentage change in minimum dataset completeness; these data are excluded from the table. ‘Tumour type’ and ‘lymph node status’ were already reported sufficiently in NR. The ‘oestrogen receptor’ and ‘progesterone receptor’ were already reported sufficiently in NR according to two studies [19, 40], but for another study, implementation of SR was needed to achieve a sufficient reporting [41]. McEvoy et al. reported increased completeness of the oestrogen receptor from 84 to 99 %; however, a decrease was seen for the progesterone receptor [41]. The implementation of SR led to an increased completeness of four parameters (‘resection margins’, ‘DCIS size’, ‘location: quadrant’ and ‘calcification’). Three parameters increased significantly in the majority of the studies ‘histological grade’ [19, 23, 40, 41], ‘lymphovascular invasion’ [19, 23, 41] and ‘lesion size’ [19, 23] or already showed sufficient completeness in NR [19, 40]. The parameters ‘distance tumour to resection margin’, ‘type of specimen’, ‘location side’, ‘multiple tumour foci’ and ‘CIS in specimen’ showed diverse results; in some studies, the parameters were already sufficiently reported in NR, whilst in other studies, implementation of SR was necessary.
Table 2

Parameter-specific completeness of the breast cancer pathology report

ArticleAppleton [23]Austin [19]Mathersa [40]McEvoy [41]
Level SRLevel 3Level 3Level 3Level 3
Origin GuidelineNHSBSPACNRCPNHMRC
Reporting formatNRSRNRSRNRSRNRSR2SR
Number of reports3010953075050385584680
Individual parameters (%)
 Lesion size63.3100*98.91008088
 Tumour type93.310097.910010098100100100
 Histological grade70100*86.3100*9610050.186.197.5*
 Lymph node status10010010099.6100100100100100
 Resection margins8010089.596.1*93.2
 Lymphovascular invasion7010089.599.7*989831.266.896.9*
 CIS in specimen80100*95.898.184100*10095.799.7
 DCIS size23.67100*43.965.9
 Type of specimen46.67100*100100
 Location, side43.33100*100100
 Location, quadrant76.67100*30.546.6*
 Multiple tumour foci22.174.3*98.297.4100
 Calcification36.891.9*82100
 ER status94.594.19010083.967.698.7*
 PR status93.488.5909883.667.371.8*

NHSBSP National Health Service Breast Screening Programme, ACN Australian Cancer Networ, RCP Royal College of Pathologists, NHMRC National Health and Medical Research Council, NR narrative report, SR synoptic report; SR2 approximately 50 % reported synoptically, ER oestrogen receptor, PR progesterone receptor

*Significant improvement in completeness according to the article

aMastectomy and biopsy merged together

Parameter-specific completeness of the breast cancer pathology report NHSBSP National Health Service Breast Screening Programme, ACN Australian Cancer Networ, RCP Royal College of Pathologists, NHMRC National Health and Medical Research Council, NR narrative report, SR synoptic report; SR2 approximately 50 % reported synoptically, ER oestrogen receptor, PR progesterone receptor *Significant improvement in completeness according to the article aMastectomy and biopsy merged together Fourteen studies on SR of colorectal cancer described a quantitative effect on parameter-specific completeness. Of these 14 studies, 13 are represented in Table 3. For colorectal cancer, we merged colon and rectal cancer data if reported separately. The results of the 14th article by Branston et al. [28], which implemented SR level 4, were calculated as the percentage change in minimum dataset completeness. These were excluded from the table. Nine studies described the effect of implementing SR level 3, and five studies described the effect of implementing SR level 4 or higher. Four individual parameters were already reported sufficiently in NR (tumour type (Fig. 3a), ‘depth of invasion’, ‘total lymph nodes’ and ‘lymph nodes with metastasis’). ‘Tumour size’ was adequately reported in the NR of three studies [18, 42, 46] but lacking in a fourth [21]. ‘Histological grade’ was sufficiently reported in the majority of studies (n = 9) but not in three other studies [26, 28, 36]. The completeness of both parameters was increased to 96–100 % after the introduction of SR. The implementation of SR led to increased completeness for the reporting of the ‘circumferential resection margin’ (Fig. 3b), ‘distant resection margins’, ‘perineural invasion’ and ‘vascular and lymphovascular invasion’. The parameters ‘stage’, ‘resection margin’ and ‘nodal status’ showed diverse results; in some studies, NR was already very good, whilst in other studies, the implementation of SR was necessary.
Table 3

Completeness of the colorectal carcinoma pathology report per individual parameter

ArticleBeattie [26]Buchwald [29]Cross [31]Idowu [36]Ihnatb [37]Porter [43]Rigby [46]Siriwardana [21]Woodsb [51]Chan [18]Casati [30]Haugland [34]Messenger [42]
Level SRLevel 3Level 3Level 3Level 3Level 3Level 3Level 3Level 3Level 3Level 4Level 5Level 5Level 6
GuidelineRCPOwnRCPCAPCAPOwnRCPRCPRCPCAPRCPRCPCAP
LocalisationCRCCRCCRCCRCCRCRectumCRCCRCCRCCRCCRCCRCRectum
Reporting formatNRSRNRSRNRSRNRSRNRSRNRSRNRSRNRSRNRSRNRSRSR3NRSRNRSR4SR5NRSR
Number of reports8586972054368414665849317720544482685494041081161131231089368112170183315
Individual parameter (%)
Tumour size10010088100*10010010098.899.4
Tumour type10010098.910010010010010010010010010010010010010098.999.4
Histological grade86100*10010076.896*10010094.4100100100981009810010098.499.996.710099.491.897.5
Resection margins54100*41.584*10010091100*5099*10080.599.7*8490.297.1*
CRM799574100*86100*093.3*24.385*70.493.2*4590*1464*7875100*73.394.995.5*86.397.4*
Invasion
Vascular68100*5298*88100*4476.398.297.780100*30.640.31888*1004196.8*
Perineural5298*23.852.7788*10013.794.0*
Lymphovascular55.990*8197*10039.398.1*
Stagea 39100*10010010010014.180*98.210077100*58.2100*2496.2*
Depth invasion10010010010010010010096.7100100
Ln status8599*60.582.4*10010010099.8100
Total LN9110098.499.997.699.1100
LN with metastasis9110099.299.797.699.1100

RCP Royal College of Pathologists, CAP College of American Pathologists, CRC colorectal carcinoma, NR narrative report, SR synoptic report, SR3 synoptic reporting 15 months after implementation, SR4 local synoptic report, SR5 national synoptic report, CRM circumferential margin (only on rectum tumours)

*Significant improvement in completeness according to the article

aTNM, but in Beattie [26] and Cross [31], Dukes was used

bColon and rectum are merged

Fig. 3

Impact of synoptic reporting on individual parameters in a colorectal specimen pathology report. a The effect of synoptic reporting on the proportion of pathology reports containing information on tumour type in colorectal cancers. b The effect of synoptic reporting on the proportion of pathology reports containing information on circumferential margin in rectal cancers. c The effect of synoptic reporting on the absolute mean number of lymph nodes resected per resection specimen. d The effect of synoptic reporting on the proportion of pathology reports reported 12 or more lymph nodes resected

Completeness of the colorectal carcinoma pathology report per individual parameter RCP Royal College of Pathologists, CAP College of American Pathologists, CRC colorectal carcinoma, NR narrative report, SR synoptic report, SR3 synoptic reporting 15 months after implementation, SR4 local synoptic report, SR5 national synoptic report, CRM circumferential margin (only on rectum tumours) *Significant improvement in completeness according to the article aTNM, but in Beattie [26] and Cross [31], Dukes was used bColon and rectum are merged Impact of synoptic reporting on individual parameters in a colorectal specimen pathology report. a The effect of synoptic reporting on the proportion of pathology reports containing information on tumour type in colorectal cancers. b The effect of synoptic reporting on the proportion of pathology reports containing information on circumferential margin in rectal cancers. c The effect of synoptic reporting on the absolute mean number of lymph nodes resected per resection specimen. d The effect of synoptic reporting on the proportion of pathology reports reported 12 or more lymph nodes resected Eight studies on SR described other cancer types, as shown in the tables (Online resources 2–6). Common parameters ‘tumour size’, ‘histological type’ and ‘histological grade’ were already reported sufficiently in NR, whereas for ‘resection margins’ and ‘(lympho)vascular/perineural invasion’, implementation of SR was necessary for an increased completeness to 96–100 %.

Quality of pathology evaluation

Implementation of SR is also expected to affect the quality of pathology evaluation. One aspect of quality is the accurate ascertainment of nodal tumour metastasis. If more lymph nodes are being resected, the N stage will be reported more accurately. For colorectal cancer, it is advised internationally to resect at least 12 lymph nodes [53]. The mean number of lymph nodes identified in the surgical specimen for colorectal cancer was evaluated in 5 of the 14 included studies [18, 29, 37, 46, 51]. All studies showed improvement in mean number of lymph nodes after implementation of SR (Fig. 3c), and more frequently, the minimum number of 12 lymph nodes was achieved. Three studies also showed an improvement of the proportion of pathology reports with a minimum of 12 lymph nodes reported after implementation of SR (Fig. 3d).

Discussion

In this systematic review, we showed that SR results in more complete pathology reports. Whilst traditional parameters such as ‘tumour type’, ‘grade’, ‘invasion depth’ and ‘nodal status’ are in general well reported with NR, other clinical relevant features such as resection margins and ‘type of local spread (vascular, lymphovascular and perineural invasion)’ are frequently lacking. The introduction of SR results in improved reporting of these parameters. SR also improves the mean number of lymph nodes reported and the proportion of pathology reports with 12 or more lymph nodes [53]. Besides these favourable quantitative outcomes, pathologists found that SR was quick and easy to complete and that reports included all essential parameters [28]. Even though SR appears to be more time-consuming in the beginning, implementation actually resulted in a significant reduction time spent on the production of the report by pathologists [54, 55]. For multidisciplinary meetings, both pathologists and clinicians appreciated consistency of the reports [56]. Necessary information for patient management was quick and unambiguous to find [28, 56]. SR can be implemented in different ways. In the studies included in the present review, the following six different implementation strategies were described: combined implementation of SR with clinical audits [23, 31, 47], organisation of SR education or meetings [18, 28, 32, 37], attachment of SR hard copy to the request form of the resection specimen [21, 31, 44], addition of explanatory notes to the SR [20, 24], mandated inclusion of essential parameters according to guidelines [33, 36, 51] or introduction of the SR module without any special attention [19, 26, 29, 30, 38, 41, 42, 46]. The implementation strategy could partially explain the success of implementation of SR. Srigley et al. described the implementation of SR in Ontario, Canada, where pilots and audits were used to ensure proper implementation of SR. In 2012, they achieved successful implementation in 92 % of all hospitals in Ontario [6]. In addition, funding for hospitals, as was used in Ontario [6, 47], could also have added to the successful implementation of SR. To date, SR has not been widely adopted in anatomic pathology reporting. The main barriers preventing successful implementation are the personal preference of pathologists, who like the flexibility and work flow of NR [57]. Whilst indeed initially, introduction is likely to disrupt the work flow, this seems a temporary situation. Flexibility is sometimes necessary to express uncertainty about a diagnosis; this can in most cases be solved by addition of free text fields to a SR. For instance, Hassel et al. [58] reported that pathologists found the SR more difficult and inflexible and they missed parameters. Another factor hampering implementation is the introduction of the new reporting format in existing work environments, such as the electronic patient files and software systems used throughout the hospital [57, 59]. As reported by Bjugn et al. [27], the development of the SR in Norway was delayed considerably because of alterations in the mandatory diagnostic criteria of the SR and because of alterations in the user interface for the SR. There are some potential limitations to our study. We are confident that with our search, we found the majority of published papers, minimising the risk of selection bias. However, publication bias may cause an overrepresentation of positive study outcomes. All studies in this review were observational. The design was either case-control or cross-sectional. No randomised controlled trial has been conducted on the effect of SR on pathology reporting. However, in our opinion, a retrospective study is suitable to investigate the effect of SR in practice. Eight studies reported the effect of SR in less than 200 reports [20, 21, 23, 37, 40, 43, 46, 48]; this is partly due to manually auditing the data for completeness. Preferably, future studies would include much higher number of pathology reports to get a better understanding of the impact of SR on pathology reporting. The fact that these studies cover different tumour types and are conducted in different countries and continents increases the generalisability. Even though most articles investigated the effect of breast and/or colon cancer, we expect that the results reported in this review are transferable to implementation of SR for other cancer types and countries not yet investigated. Based on the current data, we can conclude that SR results in improved reporting of clinical relevant data. For this reason, it is our opinion that SR is already at present the best clinical practice for anatomic pathology cancer reporting. Ongoing innovation in SR software will likely further improve the value of SR in anatomic pathology, as well as improve the ease of use and efficiency of reporting with SR modules. Supplementary information is available at Virchows Archive website. (DOCX 43 kb)
  51 in total

1.  Quality and completeness of histopathology reports of rectal cancer resections. Results of an audit in Brittany.

Authors:  Yannick Eon; Jean-Yves Le Douy; Bernard Lamer; Jean Battini; Jean-François Bretagne
Journal:  Gastroenterol Clin Biol       Date:  2006-02

2.  Pathological reporting of colorectal cancer specimens: a retrospective survey in an academic Canadian pathology department.

Authors:  Nancy G Chan; Anil Duggal; Michele M Weir; David K Driman
Journal:  Can J Surg       Date:  2008-08       Impact factor: 2.089

3.  Evidence of effectiveness of clinical audit in improving histopathology reporting standards of mastectomy specimens.

Authors:  M A Appleton; A G Douglas-Jones; J M Morgan
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

4.  Challenges and opportunities in the adoption of College of American Pathologists checklists in electronic format: perspectives and experience of Reporting Pathology Protocols Project (RPP2) participant laboratories.

Authors:  Lewis A Hassell; Anil V Parwani; Lawrence Weiss; Michael A Jones; Jay Ye
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

5.  Survival estimates after pancreatoduodenectomy skewed by non-standardized histopathology reports.

Authors:  Arne Westgaard; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  APMIS       Date:  2011-06-15       Impact factor: 3.205

6.  Adequacy of surgical pathology reporting of cancer: a College of American Pathologists Q-Probes study of 86 institutions.

Authors:  Michael O Idowu; Leonas G Bekeris; Stephen Raab; Stephen G Ruby; Raouf E Nakhleh
Journal:  Arch Pathol Lab Med       Date:  2010-07       Impact factor: 5.534

Review 7.  The staging of colorectal cancer: 2004 and beyond.

Authors:  Carolyn C Compton; Frederick L Greene
Journal:  CA Cancer J Clin       Date:  2004 Nov-Dec       Impact factor: 508.702

8.  The effect of four interventions on the informational content of histopathology reports of resected colorectal carcinomas.

Authors:  S S Cross; K M Feeley; C A Angel
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

9.  Histopathology reporting in colorectal cancer: a proforma improves quality.

Authors:  P N Siriwardana; A Pathmeswaran; J Hewavisenthi; K I Deen
Journal:  Colorectal Dis       Date:  2008-08-21       Impact factor: 3.788

10.  Standardized synoptic cancer pathology reporting: a population-based approach.

Authors:  John R Srigley; Tom McGowan; Andrea Maclean; Marilyn Raby; Jillian Ross; Sarah Kramer; Carol Sawka
Journal:  J Surg Oncol       Date:  2009-06-15       Impact factor: 3.454

View more
  38 in total

1.  An international survey-based study on colorectal cancer pathology reporting-guidelines versus local practice.

Authors:  Maria Urbanowicz; Heike I Grabsch; Frederic Fiteni; Yan Liu; Carmela Caballero; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2018-09-26       Impact factor: 4.064

Review 2.  The ins and outs of molecular pathology reporting.

Authors:  Véronique Tack; Kelly Dufraing; Zandra C Deans; Han J van Krieken; Elisabeth M C Dequeker
Journal:  Virchows Arch       Date:  2017-03-26       Impact factor: 4.064

3.  The use of structured reporting of head and neck ultrasound ensures time-efficiency and report quality during residency.

Authors:  Benjamin P Ernst; Sebastian Strieth; Fabian Katzer; Mohamed Hodeib; Jonas Eckrich; Katharina Bahr; Tobias Rader; Julian Künzel; Matthias F Froelich; Christoph Matthias; Wieland H Sommer; Sven Becker
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-14       Impact factor: 2.503

4.  Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience.

Authors:  Kersti Oselin; Nicolas Girard; Katrin Lepik; Aidi Adamson-Raieste; Tõnu Vanakesa; Ingemar Almre; Tiina Leismann; Lara Chalabreysse
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

5.  The utility of thyroid ultrasonography in the management of thyroid nodules.

Authors:  Gary Gamme; Tyler Parrington; Edward Wiebe; Sunita Ghosh; Brendan Litt; David C Williams; Todd P W McMullen
Journal:  Can J Surg       Date:  2017-04       Impact factor: 2.089

6.  Repeat preoperative endoscopy after regional implementation of electronic synoptic endoscopy reporting: a retrospective comparative study.

Authors:  Garrett G R J Johnson; Harminder Singh; Ashley Vergis; Jason Park; Olivia Hershorn; David Hochman; Ramzi M Helewa
Journal:  Surg Endosc       Date:  2021-06-08       Impact factor: 4.584

7.  Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?

Authors:  Laura A Taylor; Megan M Eguchi; Lisa M Reisch; Andrea C Radick; Hannah Shucard; Kathleen F Kerr; Michael W Piepkorn; Stevan R Knezevich; David E Elder; Raymond L Barnhill; Joann G Elmore
Journal:  Cancer       Date:  2021-05-04       Impact factor: 6.860

8.  New Operative Reporting Standards: Where We Stand Now and Opportunities for Innovation.

Authors:  Jacqueline M Soegaard Ballester; Kristin E Goodsell; Jae P Ermer; Giorgos C Karakousis; John T Miura; Nicole M Saur; Najjia N Mahmoud; Ari Brooks; Julia C Tchou; Peter E Gabriel; Lawrence N Shulman; Heather Wachtel
Journal:  Ann Surg Oncol       Date:  2021-09-14       Impact factor: 5.344

9.  Automated Generation of Synoptic Reports from Narrative Pathology Reports in University Malaya Medical Centre Using Natural Language Processing.

Authors:  Wee-Ming Tan; Kean-Hooi Teoh; Mogana Darshini Ganggayah; Nur Aishah Taib; Hana Salwani Zaini; Sarinder Kaur Dhillon
Journal:  Diagnostics (Basel)       Date:  2022-04-01

10.  Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States.

Authors:  Matthew P Smeltzer; Yu-Sheng Lee; Nicholas R Faris M Div; Carrie Fehnel; Olawale Akinbobola; Meghan Meadows-Taylor; David Spencer; Elizabeth Sales; Sherry Okun; Christopher Giampapa; Amal Anga; Alicia Pacheco; Meredith A Ray; Raymond U Osarogiagbon
Journal:  J Thorac Oncol       Date:  2021-07-16       Impact factor: 20.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.